MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com

A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Phase 1
Completed
Conditions
Hemophilia A
Hemophilia B
Interventions
Drug: BAY1093884
First Posted Date
2015-10-08
Last Posted Date
2018-10-18
Lead Sponsor
Bayer
Target Recruit Count
32
Registration Number
NCT02571569

Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates

Phase 1
Completed
Conditions
Thromboembolism
Interventions
First Posted Date
2015-10-01
Last Posted Date
2018-07-10
Lead Sponsor
Bayer
Target Recruit Count
10
Registration Number
NCT02564718

Inhalation Flow Rate-study

Phase 1
Completed
Conditions
Bronchiectasis
Interventions
Device: T-326 Inhaler
First Posted Date
2015-09-30
Last Posted Date
2017-04-26
Lead Sponsor
Bayer
Target Recruit Count
33
Registration Number
NCT02563197

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)

Phase 3
Active, not recruiting
Conditions
Hypertension, Pulmonary
Interventions
First Posted Date
2015-09-29
Last Posted Date
2024-12-12
Lead Sponsor
Bayer
Target Recruit Count
24
Registration Number
NCT02562235
Locations
🇩🇪

Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany

🇮🇹

Azienda Ospedale-Università di Padova - UOC Cardiologia Pediatrica, Padova, Veneto, Italy

🇨🇴

Clínica Imbanaco S.A.S, Cali, Valle Del Cauca, Colombia

and more 13 locations

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2015-09-24
Last Posted Date
2022-11-01
Lead Sponsor
Bayer
Target Recruit Count
2540
Registration Number
NCT02558465
Locations
🇯🇵

Many locations, Multiple Locations, Japan

An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers

Completed
Conditions
Prevention and Control
Stroke
Atrial Fibrillation
Interventions
Drug: Direct Oral Anticoagulant (DOAC)
First Posted Date
2015-09-24
Last Posted Date
2017-02-16
Lead Sponsor
Bayer
Target Recruit Count
247
Registration Number
NCT02559232

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Phase 3
Terminated
Conditions
Transcatheter Aortic Valve Replacement
Interventions
First Posted Date
2015-09-22
Last Posted Date
2020-01-13
Lead Sponsor
Bayer
Target Recruit Count
1653
Registration Number
NCT02556203

Interaction With HIV Antiretroviral Agents

First Posted Date
2015-09-22
Last Posted Date
2017-12-06
Lead Sponsor
Bayer
Target Recruit Count
40
Registration Number
NCT02556268

Special Drug Use Investigation of Ciproxan Injection in Pediatrics

Completed
Conditions
Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
Interventions
First Posted Date
2015-09-21
Last Posted Date
2020-02-28
Lead Sponsor
Bayer
Target Recruit Count
48
Registration Number
NCT02555059

Russia/Ukraine Suppression of Ovarian Activity Study

Phase 2
Completed
Conditions
Contraception
Interventions
Drug: Gestodene/EE Patch (BAY86-5016)
First Posted Date
2015-09-16
Last Posted Date
2017-08-07
Lead Sponsor
Bayer
Target Recruit Count
91
Registration Number
NCT02550977
© Copyright 2025. All Rights Reserved by MedPath